Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- OVID
- Price
- 1.75
- Stock movement up
- +0.11 (6.71%)
- Company name
- Ovid Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 124.62M
- Ent value
- 123.16M
- Price/Sales
- 18.85
- Price/Book
- 2.79
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -24.72%
- 1 year return (CAGR)
- 150.64%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
OVID does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 18.85 |
| Price to Book | 2.79 |
| EV to Sales | 18.63 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 71.21M |
| EPS (TTM) | -0.51 |
| FCF per share (TTM) | -0.53 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.61M |
| Gross profit (TTM) | 6.59M |
| Operating income (TTM) | -40.87M |
| Net income (TTM) | -36.33M |
| EPS (TTM) | -0.51 |
| EPS (1y forward) | -0.37 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 99.74% |
| Operating margin (TTM) | -618.28% |
| Profit margin (TTM) | -549.62% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 20.61M |
| Net receivables | 0.00 |
| Total current assets | 28.82M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 13.76M |
| Total assets | 63.85M |
| Accounts payable | 1.71M |
| Short/Current long term debt | 13.76M |
| Total current liabilities | 6.80M |
| Total liabilities | 19.15M |
| Shareholder's equity | 44.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -37.93M |
| Capital expenditures (TTM) | 44.00K |
| Free cash flow (TTM) | -37.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -81.28% |
| Return on Assets | -56.90% |
| Return on Invested Capital | -78.80% |
| Cash Return on Invested Capital | -82.37% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.68 |
| Daily high | 1.77 |
| Daily low | 1.65 |
| Daily Volume | 2.43M |
| All-time high | 15.00 |
| 1y analyst estimate | 4.05 |
| Beta | 0.05 |
| EPS (TTM) | -0.51 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 16 Mar 2026 |
Downside potential
Loading...
Downside potential data
| OVID | S&P500 | |
| Current price drop from All-time high | -88.33% | -0.89% |
| Highest price drop | -98.30% | -19.00% |
| Date of highest drop | 10 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -93.83% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
124.62M
Marketcap category
Small-cap
Description
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Employees
23
Website
Investor relations
-
SEC filings
CEO
Jeremy Max Levin
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page